文献速递重症综合管理与镇静镇痛心脑血管急症

镁补充与快速性心律失常:一项非随机临床试验

Magnesium Supplementation and Tachyarrhythmias: A Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Intern Med · 2026-01-01
一句话结论在93个ICU中,对血清镁接近常规治疗切点的患者补充镁,未降低24小时内快速性心律失常、低血压或死亡风险。

该非随机临床试验纳入2003至2022年美国与欧洲93个ICU中接受血清镁检测的成人患者,采用模糊回归断点设计,比较血清镁恰在补充切点两侧患者的结局,评估1.6至2.0 mg/dL范围内多个现行治疗切点。共纳入171727例ICU住院的478901个24小时治疗窗,平均年龄63岁,女性42.4%。镁补充与快速性心律失常风险差异0.1%(95%CI -4.2至6.9)、低血压风险差异1.2%(95%CI -0.9至17.7)、死亡风险差异1.4%(95%CI -0.6至5.3)均无显著关联,且在各切点水平一致。作者结论认为,对血清镁接近现行切点的患者,按当前剂量和阈值常规补充镁未显示获益。

要点

  • 在93个ICU的171727例住院、478901个24小时治疗窗中,镁补充与24小时内快速性心律失常风险差异0.1%(95%CI -4.2至6.9),无显著关联。
  • 镁补充与低血压风险差异1.2%(95%CI -0.9至17.7)、死亡风险差异1.4%(95%CI -0.6至5.3),均无显著关联。
  • 上述无显著关联的结果在1.6 mg/dL至2.0 mg/dL所有评估的补充切点水平上一致。
  • 研究采用模糊回归断点设计,比较血清镁恰在机构常规治疗切点两侧的患者,以减少适应证混杂。
  • 作者结论:对血清镁接近现行切点的患者,按当前剂量和阈值常规补充镁未显示获益。

适用人群与场景

  • 美国与欧洲93个ICU中接受血清镁检测的成人ICU患者,2003至2022年。
  • 分析纳入171727例ICU住院的478901个24小时治疗窗;女性72767例(42.4%),男性98960例(57.6%),平均(SD)年龄63(16)岁。

诊断标准与关键阈值

  • 以各机构常规治疗切点定义低镁血症并决定是否补充,评估的切点范围为1.6 mg/dL至2.0 mg/dL。

研究设计与关键结果

  • 非随机临床试验,采用模糊回归断点设计,比较血清镁恰在补充资格切点两侧患者的结局,覆盖1.6至2.0 mg/dL范围内多个现行治疗切点。
  • 主要终点为镁检测后24小时内室性或室上性快速性心律失常,镁补充的风险差异为0.1%(95%CI -4.2至6.9),无显著关联,且在所有评估的切点水平一致。
  • 次要终点低血压风险差异1.2%(95%CI -0.9至17.7),死亡风险差异1.4%(95%CI -0.6至5.3),均无显著关联。

证据类型、等级与局限

  • 证据类型:非随机临床试验(准实验设计,模糊回归断点分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,对血清镁接近现行治疗切点的患者,按当前剂量和阈值常规补充镁未显示获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Magnesium supplementation is regularly given to acutely ill patients with serum levels below the standard reference range, primarily for the prevention of tachyarrhythmias, such as atrial fibrillation. The evidence for this practice and the specific treatment thresholds used is limited. Conventional observational studies of this question are at risk of confounding by indication and other biases.

OBJECTIVE: To determine whether giving magnesium supplementation to patients with hypomagnesemia, as defined by a given institution's usual treatment cutoff, reduces adverse clinical outcome using a quasi-experimental study design that plausibly allows for causal inference.

DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized clinical trial of intensive care unit (ICU) patients undergoing serum magnesium testing was conducted in 93 ICUs across the US and Europe between 2003 and 2022. A fuzzy regression discontinuity design was used, in which individuals just either side of the eligibility cutoff for magnesium supplementation were compared with regard to the study outcomes. This comparison was performed across a range of treatment cutoffs in current use, ranging from 1.6 mg/dL to 2.0 mg/dL. Data were analyzed from August to October 2025.

EXPOSURES: Magnesium supplementation.

MAIN OUTCOMES AND MEASURES: The primary outcome was ventricular or supraventricular tachyarrhythmia in the 24 hours after magnesium testing. Secondary outcomes were the occurrence of hypotension or death.

RESULTS: A total of 478 901 twenty-four-hour treatment windows from 171 727 ICU admissions were included in the study. A total of 72 767 admitted patients (42.4%) were female, 98 960 (57.6%) were male, and the mean (SD) age of the cohort was 63 (16) years. There was no evidence of an effect of magnesium supplementation on the occurrence of tachyarrhythmia, with a risk difference of 0.1% (95% CI, -4.2 to 6.9). This was true across all the cutoff levels evaluated. There was similarly no association with the occurrence of hypotension (risk difference, 1.2%; 95% CI, -0.9 to 17.7) or death (risk difference, 1.4%; 95% CI, -0.6 to 5.3).

CONCLUSIONS AND RELEVANCE: In this nonrandomized clinical trial, routine supplementation of magnesium with currently used doses and treatment thresholds was not associated with beneficial effects for individuals with serum magnesium values close to those cutoffs.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Goulden R, Abrahamowicz M, Strumpf E, et al. Magnesium Supplementation and Tachyarrhythmias: A Nonrandomized Clinical Trial. JAMA Intern Med. 2026. PMID: 41359319. doi:10.1001/jamainternmed.2025.6572

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。